Menu

Image of the Day: Cellular Destiny

Progenitor cells in the pancreas of humans get developmental cues from proteins in their environment.

Dec 11, 2018
Carolyn Wilke
An embryonic pancreatic bud that was grown ex vivo from human cells
DANSTEM

R

esearchers have cracked the code that guides immature human pancreatic cells to their destiny. The results of this study, published in Nature on November 28, could help scientists direct stem cells to grow into the insulin-producing ones for potential use in replacement therapy for type 1 diabetes.

The researchers attached pancreatic progenitor cells, which are similar to stem cells but have a limited capacity to replicate, to a glass slide that was covered in different types of proteins. They could then watch how the cells reacted to the proteins without the interference of neighbor cells. They also observed mechanical force changes inside each cell that cued its development. Specifically, the protein laminin prodded progenitor cells into becoming endocrine cells, such as the insulin-producing beta cell, by reducing their mechanical force. 

These results provide the tools “to more precisely engineer cells that are lost or damaged in severe diseases, such as type 1 diabetes and neurodegenerative diseases, for future cell replacement therapies,” study author Henrick Semb says in a statement.

A. Mamidi, et al., “Mechanosignalling via integrins directs fate decisions of pancreatic progenitors,” Naturedoi:10.1038/s41586-018-0762-2, 2018.

March 2019

Going Under

Dissecting the effects of anesthetics

Marketplace

Sponsored Product Updates

The Complex Biology of Macrophages: Origins, Functions, and Activation States
The Complex Biology of Macrophages: Origins, Functions, and Activation States
Download this poster from R&D Systems for a detailed overview of macrophage markers, functions, development, specialization, and activation!
A Guide to Measuring Drug-Target Residence Times with Biochemical Assays
A Guide to Measuring Drug-Target Residence Times with Biochemical Assays
Download this guide from BellBrook Labs to learn about how to use Transcreener® biochemical assays to measure drug-target residence times, complete with examples and case studies!
Beckman Coulter Life Sciences To Launch New Product Via Live Stream Event
Beckman Coulter Life Sciences To Launch New Product Via Live Stream Event
After visiting labs around the world to identify ways to advance its industry-leading cell counting technology, Beckman Coulter Life Sciences will host a live streaming event on March 26 at 10 a.m. EDT / 7 a.m. PDT to announce its latest product innovation.  
Cybrexa Therapeutics to Present First Data and Unveil Details for its alphalex™-PARP Inhibitor Lead Candidate CBX-11 at AACR Annual Meeting 2019
Cybrexa Therapeutics to Present First Data and Unveil Details for its alphalex™-PARP Inhibitor Lead Candidate CBX-11 at AACR Annual Meeting 2019
Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, today announced that Vishwas Paralkar, PhD, Chief Scientific Officer of Cybrexa, will present the first set of preclinical data supporting its alphalex™-PARP inhibitor lead candidate, CBX-11, at the American Association for Cancer Research (AACR) Annual Meeting 2019, being held March 29 – April 3 in Atlanta, Georgia. At the meeting, the Company will unveil the FDA-approved poly ADP-ribose polymerase (PARP) inhibitor conjugated in CBX-11.